Cargando…
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
IMPORTANCE: Patients with cancer undergoing treatment are at high risk of COVID-19 following SARS-CoV-2 infection; however, their ability to produce an adequate antibody response to messenger RNA SARS-CoV-2 vaccines is unclear. OBJECTIVE: To evaluate rates of antispike (anti-S) antibody response to...
Autores principales: | Massarweh, Amir, Eliakim-Raz, Noa, Stemmer, Amos, Levy-Barda, Adva, Yust-Katz, Shlomit, Zer, Alona, Benouaich-Amiel, Alexandra, Ben-Zvi, Haim, Moskovits, Neta, Brenner, Baruch, Bishara, Jihad, Yahav, Dafna, Tadmor, Boaz, Zaks, Tal, Stemmer, Salomon M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164144/ https://www.ncbi.nlm.nih.gov/pubmed/34047765 http://dx.doi.org/10.1001/jamaoncol.2021.2155 |
Ejemplares similares
-
Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study
por: Massarweh, Amir, et al.
Publicado: (2022) -
Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment
por: Eliakim-Raz, Noa, et al.
Publicado: (2021) -
Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: a prospective cohort study
por: Eliakim-Raz, Noa, et al.
Publicado: (2022) -
Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years
por: Bar-Haim, Erez, et al.
Publicado: (2022) -
Risk-factors for re-admission and outcome of patients hospitalized with confirmed COVID-19
por: Green, Hefziba, et al.
Publicado: (2021)